All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

glipizide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antihyperglycaemics	1301	29094-61-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: glypidizine glidiazinamide K 4024 K-4024 K4024 glipizide dipazide glibenese glipizid glucotrol glucozide glupizide glydiazinamide melizide napizide sucrazide	An oral hypoglycemic agent which is rapidly absorbed and completely metabolized. Molecular weight: 445.54 Formula: C21H27N5O4S CLOGP: 2.60 LIPINSKI: 0 HAC: 9 HDO: 3 TPSA: 130.15 ALOGS: -4.43 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
10	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	4.50 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.96 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	95 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.16 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.56 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.02 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	3.30 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
May 8, 1984	FDA	PFIZER

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Blood glucose increased	688.58	11.84	480	34440	74671	56182476
Hypoglycaemia	405.24	11.84	310	34610	55505	56201642
Cardiac failure congestive	313.10	11.84	326	34594	87394	56169753
Blood glucose decreased	281.86	11.84	165	34755	18922	56238225
Myocardial infarction	193.05	11.84	262	34658	92608	56164539
Coronary artery disease	184.69	11.84	153	34767	30643	56226504
Rheumatoid arthritis	154.49	11.84	26	34894	382578	55874569
Diabetes mellitus inadequate control	146.00	11.84	97	34823	13883	56243264
Product residue present	123.87	11.84	56	34864	3739	56253408
Cerebrovascular accident	116.99	11.84	216	34704	99054	56158093
Glycosylated haemoglobin increased	98.91	11.84	70	34850	11095	56246052
Blood glucose fluctuation	84.89	11.84	45	34875	4250	56252897
Pancreatitis	82.87	11.84	120	34800	44960	56212187
Diabetes mellitus	80.84	11.84	129	34791	52606	56204541
Infusion related reaction	74.30	11.84	19	34901	208912	56048235
Drug intolerance	72.36	11.84	37	34883	264781	55992366
Treatment failure	72.25	11.84	10	34910	170382	56086765
Systemic lupus erythematosus	68.77	11.84	14	34906	180064	56077083
Off label use	68.14	11.84	153	34767	556027	55701120
Product complaint	67.51	11.84	57	34863	11703	56245444
Synovitis	67.15	11.84	10	34910	161295	56095852
Lactic acidosis	66.29	11.84	95	34825	35251	56221896
Exposure during pregnancy	65.53	11.84	5	34915	136337	56120810
Drug ineffective	63.89	11.84	324	34596	918665	55338482
Glossodynia	62.21	11.84	10	34910	152448	56104699
Hyperglycaemia	56.41	11.84	92	34828	38189	56218958
Hypoglycaemic coma	56.03	11.84	28	34892	2339	56254808
Renal failure	53.10	11.84	170	34750	110330	56146817
Pericarditis	52.32	11.84	4	34916	108919	56148228
Joint swelling	50.91	11.84	63	34857	289737	55967410
Euglycaemic diabetic ketoacidosis	50.86	11.84	29	34891	3160	56253987
Lower respiratory tract infection	50.43	11.84	6	34914	114788	56142359
Blood glucose abnormal	49.86	11.84	39	34881	7189	56249958
Mental status changes	48.46	11.84	85	34835	37416	56219731
Arthropathy	46.30	11.84	34	34886	200241	56056906
Product use issue	43.76	11.84	31	34889	186010	56071137
General physical health deterioration	43.15	11.84	26	34894	169984	56087163
Wound	41.59	11.84	17	34903	138787	56118360
Product dose omission issue	40.56	11.84	241	34679	204512	56052635
Diabetic ketoacidosis	40.29	11.84	54	34866	18817	56238330
Chest pain	39.93	11.84	227	34693	189570	56067577
Ischaemic cardiomyopathy	39.14	11.84	22	34898	2332	56254815
Discomfort	38.39	11.84	20	34900	141741	56115406
Acute kidney injury	37.66	11.84	267	34653	240496	56016651
Musculoskeletal stiffness	36.68	11.84	26	34894	155981	56101166
Dehydration	35.42	11.84	193	34727	158632	56098515
Pyrexia	35.34	11.84	137	34783	418636	55838511
C-reactive protein increased	34.83	11.84	4	34916	78680	56178467
Cutaneous T-cell dyscrasia	33.77	11.84	8	34912	62	56257085
Oedema peripheral	33.53	11.84	201	34719	171053	56086094
Acute myocardial infarction	33.10	11.84	64	34856	30329	56226818
Helicobacter infection	31.75	11.84	4	34916	73264	56183883
Asthenia	31.44	11.84	338	34582	342635	55914512
Weight decreased	30.41	11.84	254	34666	240460	56016687
Alopecia	30.20	11.84	88	34832	293370	55963777
Swelling	30.03	11.84	65	34855	239706	56017441
Thrombosis	29.97	11.84	93	34827	59334	56197813
Transient ischaemic attack	29.83	11.84	65	34855	33512	56223635
Diabetic neuropathy	29.77	11.84	22	34898	3726	56253421
Myocardial ischaemia	29.50	11.84	37	34883	12079	56245068
Nodular rash	29.46	11.84	9	34911	196	56256951
Cardiac disorder	28.12	11.84	77	34843	45810	56211337
Urinary tract infection	26.35	11.84	246	34674	240267	56016880
Hepatic enzyme increased	26.31	11.84	41	34879	171343	56085804
Product appearance confusion	26.25	11.84	6	34914	39	56257108
Gout	26.13	11.84	35	34885	12186	56244961
Chronic obstructive pulmonary disease	25.47	11.84	86	34834	57329	56199818
Stool analysis abnormal	24.34	11.84	6	34914	56	56257091
Chronic kidney disease	24.23	11.84	69	34851	41987	56215160
Arthralgia	23.86	11.84	198	34722	501471	55755676
Therapeutic product effect decreased	23.74	11.84	43	34877	169409	56087738
Renal injury	23.02	11.84	28	34892	8859	56248288
Pancreatitis acute	22.73	11.84	49	34871	25075	56232072
Pernicious anaemia	22.51	11.84	10	34910	640	56256507
Drug abuse	22.43	11.84	7	34913	67603	56189544
Dizziness	21.88	11.84	341	34579	375799	55881348
Nausea	21.60	11.84	623	34297	763555	55493592
Cardiovascular disorder	21.49	11.84	30	34890	10859	56246288
Ventricular hypertrophy	21.32	11.84	17	34903	3221	56253926
Product use in unapproved indication	21.31	11.84	34	34886	140788	56116359
Coronary artery occlusion	21.09	11.84	25	34895	7704	56249443
Diarrhoea	21.00	11.84	531	34389	637976	55619171
Condition aggravated	20.82	11.84	127	34793	344771	55912376
Hypoacusis	20.32	11.84	43	34877	21725	56235422
Treatment noncompliance	18.28	11.84	53	34867	32570	56224577
Injection site nodule	18.06	11.84	16	34904	3503	56253644
Irritable bowel syndrome	18.02	11.84	10	34910	68448	56188699
Acute coronary syndrome	17.93	11.84	26	34894	9742	56247405
Suicide attempt	17.45	11.84	7	34913	57829	56199318
Ventricular dysfunction	17.41	11.84	14	34906	2685	56254462
Hyperinsulinaemia	16.63	11.84	5	34915	103	56257044
Haemorrhage intracranial	16.59	11.84	29	34891	12726	56244421
Rhabdomyolysis	16.38	11.84	59	34861	40599	56216548
Product quality issue	16.30	11.84	50	34870	31686	56225461
Pancreatitis haemorrhagic	15.79	11.84	7	34913	446	56256701
Abortion spontaneous	15.49	11.84	4	34916	43749	56213398
Angina unstable	15.30	11.84	20	34900	6801	56250346
Death	14.98	11.84	296	34624	341130	55916017
Angioedema	14.91	11.84	58	34862	41395	56215752
Adenocarcinoma pancreas	14.88	11.84	9	34911	1093	56256054
Blood potassium increased	14.86	11.84	33	34887	17228	56239919
Dilatation atrial	14.84	11.84	11	34909	1872	56255275
Type 2 diabetes mellitus	14.81	11.84	63	34857	46799	56210348
Haemodialysis	14.53	11.84	22	34898	8569	56248578
Parosmia	14.13	11.84	16	34904	4695	56252452
Cellulitis	14.03	11.84	87	34833	74862	56182285
Leukopenia	13.99	11.84	14	34906	70926	56186221
Hypervolaemia	13.89	11.84	42	34878	26416	56230731
Hyperlipidaemia	13.80	11.84	33	34887	18076	56239071
Emotional distress	13.56	11.84	45	34875	29718	56227429
Accidental poisoning	13.46	11.84	7	34913	636	56256511
Fear	13.40	11.84	29	34891	14879	56242268
Acute respiratory failure	13.37	11.84	46	34874	30948	56226199
Blood triglycerides increased	13.22	11.84	25	34895	11652	56245495
Peripheral vascular disorder	13.17	11.84	17	34903	5708	56251439
Coronary artery stenosis	13.10	11.84	15	34905	4453	56252694
Glucose urine present	12.91	11.84	7	34913	692	56256455
Decreased appetite	12.81	11.84	199	34721	219032	56038115
Hip arthroplasty	12.81	11.84	4	34916	38619	56218528
Unevaluable event	12.74	11.84	61	34859	47626	56209521
Cardiomegaly	12.54	11.84	30	34890	16437	56240710
Essential hypertension	12.51	11.84	15	34905	4678	56252469
Abdominal discomfort	12.44	11.84	111	34809	277163	55979984
Hypoglycaemic seizure	12.40	11.84	6	34914	467	56256680
Vision blurred	12.36	11.84	91	34829	82852	56174295
International normalised ratio increased	12.25	11.84	57	34863	43984	56213163
Therapeutic product effect incomplete	12.24	11.84	30	34890	106001	56151146
Hypersensitivity	12.24	11.84	101	34819	256307	56000840
Fluid retention	12.23	11.84	66	34854	54012	56203135
Blood pressure fluctuation	11.99	11.84	5	34915	40355	56216792
Nasopharyngitis	11.98	11.84	84	34836	220875	56036272
Renal disorder	11.96	11.84	43	34877	29562	56227585
Infection	11.92	11.84	74	34846	200132	56057015

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hypoglycaemia	667.23	11.74	517	36175	50429	31610223
Blood glucose increased	541.45	11.74	495	36197	60588	31600064
Cardiac failure congestive	291.94	11.74	407	36285	78980	31581672
Myocardial infarction	264.73	11.74	472	36220	112982	31547670
Coronary artery disease	185.40	11.74	247	36445	45840	31614812
Blood glucose decreased	174.75	11.74	132	36560	12339	31648313
Completed suicide	135.90	11.74	316	36376	91198	31569454
Off label use	110.05	11.74	145	36547	347129	31313523
Glycosylated haemoglobin increased	93.25	11.74	85	36607	10315	31650337
Cerebrovascular accident	86.30	11.74	244	36448	79240	31581412
Drug abuse	81.66	11.74	5	36687	87753	31572899
Pancreatitis	63.72	11.74	133	36559	35638	31625014
Product complaint	61.32	11.74	51	36641	5473	31655179
Blood glucose abnormal	58.47	11.74	49	36643	5314	31655338
Diabetes mellitus inadequate control	50.72	11.74	68	36624	12673	31647979
Product residue present	48.70	11.74	33	36659	2597	31658055
Injury	45.77	11.74	82	36610	19627	31641025
General physical health deterioration	45.08	11.74	39	36653	113396	31547256
Myocardial ischaemia	44.81	11.74	74	36618	16593	31644059
Product use in unapproved indication	44.64	11.74	30	36662	99141	31561511
Mental status changes	44.57	11.74	116	36576	35852	31624800
Febrile neutropenia	40.36	11.74	49	36643	121800	31538852
Cardiac disorder	40.19	11.74	118	36574	39096	31621556
Ischaemic cardiomyopathy	39.35	11.74	41	36651	5856	31654796
C-reactive protein increased	36.92	11.74	6	36686	48644	31612008
Diabetic neuropathy	36.81	11.74	33	36659	3916	31656736
Cardiovascular disorder	35.73	11.74	49	36643	9329	31651323
Interstitial lung disease	34.38	11.74	14	36678	61389	31599263
Blood glucose fluctuation	31.50	11.74	30	36662	3845	31656807
Spur cell anaemia	29.78	11.74	8	36684	54	31660598
Pyrexia	29.69	11.74	218	36474	303622	31357030
Diabetes mellitus	29.31	11.74	112	36580	42444	31618208
Neutropenia	28.08	11.74	77	36615	140287	31520365
Autoimmune myocarditis	27.74	11.74	10	36682	193	31660459
Myasthenic syndrome	26.96	11.74	12	36680	408	31660244
Emotional distress	26.28	11.74	54	36638	14302	31646350
Pancreatitis acute	26.19	11.74	77	36615	25523	31635129
Transient ischaemic attack	25.23	11.74	73	36619	23983	31636669
Hypophagia	24.20	11.74	68	36624	21974	31638678
Diabetic ketoacidosis	23.53	11.74	57	36635	16848	31643804
Arteriosclerosis	22.73	11.74	43	36649	10724	31649928
Asthenia	22.45	11.74	375	36317	224380	31436272
Angina unstable	21.55	11.74	43	36649	11152	31649500
Acute myocardial infarction	20.95	11.74	115	36577	50708	31609944
Arteriosclerosis coronary artery	20.32	11.74	42	36650	11166	31649486
Product dose omission issue	19.82	11.74	198	36494	105388	31555264
Type 2 diabetes mellitus	19.67	11.74	49	36643	14735	31645917
Rheumatoid arthritis	19.51	11.74	16	36676	47793	31612859
Drug ineffective	19.38	11.74	332	36360	395241	31265411
Bladder cancer	18.75	11.74	48	36644	14677	31645975
Unresponsive to stimuli	18.67	11.74	69	36623	25731	31634921
Anhedonia	18.62	11.74	32	36660	7410	31653242
Cardiomyopathy	18.52	11.74	49	36643	15284	31645368
Gastrointestinal mucosal necrosis	17.85	11.74	7	36685	172	31660480
Interstitial granulomatous dermatitis	17.81	11.74	7	36685	173	31660479
Autoimmune myositis	17.69	11.74	6	36686	96	31660556
Drug resistance	17.55	11.74	3	36689	23450	31637202
Leukopenia	17.34	11.74	25	36667	57803	31602849
Renal injury	17.08	11.74	38	36654	10627	31650025
Hyperglycaemia	16.72	11.74	85	36607	36391	31624261
Intentional product use issue	16.15	11.74	20	36672	49327	31611325
Glycosylated haemoglobin decreased	15.67	11.74	8	36684	371	31660281
Poor quality product administered	15.35	11.74	14	36678	1699	31658953
Agranulocytosis	15.29	11.74	3	36689	21244	31639408
Product quality issue	15.10	11.74	47	36645	16064	31644588
Altered state of consciousness	15.09	11.74	3	36689	21048	31639604
Diverticulum	15.05	11.74	27	36665	6467	31654185
Alanine aminotransferase increased	14.88	11.74	41	36651	74615	31586037
Acute kidney injury	14.81	11.74	426	36266	279288	31381364
Suicide attempt	14.54	11.74	13	36679	37235	31623417
COVID-19	14.28	11.74	26	36666	54795	31605857
Infusion related reaction	14.19	11.74	21	36671	48034	31612618
Peripheral vascular disorder	14.13	11.74	22	36670	4694	31655958
Treatment failure	13.92	11.74	16	36676	40776	31619876
Weight decreased	13.84	11.74	261	36431	159691	31500961
Product use issue	13.84	11.74	28	36664	56731	31603921
Condition aggravated	13.52	11.74	123	36569	163886	31496766
Chest pain	13.48	11.74	200	36492	116757	31543895
Mucosal inflammation	13.46	11.74	12	36680	34415	31626237
Drug intolerance	13.27	11.74	25	36667	52008	31608644
Cytomegalovirus infection	13.24	11.74	6	36686	24701	31635951
Hepatic function abnormal	13.19	11.74	17	36675	41205	31619447
Electrocardiogram ST-T change	13.06	11.74	8	36684	529	31660123
Pancreatic carcinoma	13.05	11.74	30	36662	8570	31652082
Blood pressure fluctuation	13.02	11.74	5	36687	22731	31637921
Hyphaema	13.02	11.74	8	36684	532	31660120
Neutrophil count decreased	13.00	11.74	21	36671	46373	31614279
Vision blurred	12.93	11.74	88	36604	41827	31618825
Human anaplasmosis	12.92	11.74	4	36688	47	31660605
Fatigue	12.74	11.74	491	36201	334715	31325937
Renal failure	12.73	11.74	207	36485	123123	31537529
Treatment noncompliance	12.58	11.74	61	36631	25623	31635029
Coronary artery occlusion	12.41	11.74	33	36659	10323	31650329
Fear	12.17	11.74	32	36660	9942	31650710
Lower respiratory tract infection	12.09	11.74	9	36683	28228	31632424
Glycosylated haemoglobin abnormal	12.04	11.74	5	36687	143	31660509
Contraindicated product administered	11.92	11.74	4	36688	19768	31640884
Chronic kidney disease	11.88	11.74	80	36612	37895	31622757

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hypoglycaemia	1058.60	11.54	746	54649	93618	70779431
Blood glucose increased	840.32	11.54	673	54722	102309	70770740
Cardiac failure congestive	497.72	11.54	570	54825	134887	70738162
Myocardial infarction	462.63	11.54	618	54777	171027	70702022
Blood glucose decreased	346.99	11.54	223	55172	23936	70849113
Coronary artery disease	318.93	11.54	314	55081	62422	70810627
Cerebrovascular accident	194.32	11.54	378	55017	143092	70729957
Completed suicide	158.35	11.54	462	54933	226673	70646376
Rheumatoid arthritis	154.85	11.54	22	55373	291783	70581266
Off label use	151.07	11.54	217	55178	742843	70130206
Glycosylated haemoglobin increased	142.20	11.54	114	55281	17277	70855772
Product residue present	120.95	11.54	57	55338	3313	70869736
Diabetes mellitus inadequate control	105.17	11.54	108	55287	22537	70850512
Pancreatitis	95.78	11.54	174	55221	62494	70810555
Mental status changes	88.68	11.54	169	55226	62932	70810117
Product complaint	85.05	11.54	73	55322	12158	70860891
Drug ineffective	85.00	11.54	412	54983	939340	69933709
Contraindicated product administered	84.99	11.54	5	55390	134607	70738442
Drug intolerance	83.26	11.54	36	55359	225651	70647398
Drug abuse	83.18	11.54	9	55386	147247	70725802
Ischaemic cardiomyopathy	79.04	11.54	56	55339	7048	70866001
Blood glucose abnormal	74.64	11.54	61	55334	9496	70863553
Infusion related reaction	73.66	11.54	31	55364	197503	70675546
General physical health deterioration	71.92	11.54	48	55347	235983	70637066
Diabetes mellitus	70.31	11.54	166	55229	71658	70801391
Cardiac disorder	67.84	11.54	146	55249	59269	70813780
Lactic acidosis	66.62	11.54	153	55242	64871	70808178
Blood glucose fluctuation	66.50	11.54	48	55347	6219	70866830
Synovitis	65.62	11.54	11	55384	129217	70743832
Myocardial ischaemia	64.77	11.54	87	55308	24113	70848936
Euglycaemic diabetic ketoacidosis	63.72	11.54	46	55349	5961	70867088
Treatment failure	63.52	11.54	17	55378	144125	70728924
Acute myocardial infarction	63.41	11.54	161	55234	72726	70800323
Hyperglycaemia	61.70	11.54	148	55247	64524	70808525
C-reactive protein increased	57.02	11.54	9	55386	110508	70762541
Acute kidney injury	56.75	11.54	593	54802	474031	70399018
Hand deformity	55.24	11.54	3	55392	86479	70786570
Cardiovascular disorder	54.18	11.54	66	55329	16604	70856445
Lower respiratory tract infection	53.66	11.54	11	55384	111902	70761147
Diabetic neuropathy	53.50	11.54	41	55354	5817	70867232
Diabetic ketoacidosis	52.65	11.54	91	55304	31421	70841628
Transient ischaemic attack	52.56	11.54	113	55282	45831	70827218
Pyrexia	51.31	11.54	272	55123	606680	70266369
Product use in unapproved indication	51.05	11.54	52	55343	207426	70665623
Product dose omission issue	49.61	11.54	315	55080	217153	70655896
Renal failure	48.27	11.54	282	55113	188788	70684261
Hypoglycaemic coma	47.64	11.54	34	55361	4327	70868722
Asthenia	47.00	11.54	555	54840	457111	70415938
Chest pain	43.85	11.54	341	55054	250919	70622130
Pericarditis	41.29	11.54	8	55387	84697	70788352
Angina unstable	40.80	11.54	56	55339	15837	70857212
Arthropathy	39.96	11.54	35	55360	150022	70723027
Systemic lupus erythematosus	39.59	11.54	15	55380	101887	70771162
Product use issue	38.94	11.54	50	55345	179887	70693162
Hypophagia	38.43	11.54	94	55301	41476	70831573
Chronic obstructive pulmonary disease	36.18	11.54	138	55257	77503	70795546
Joint swelling	35.46	11.54	92	55303	253119	70619930
Musculoskeletal stiffness	35.24	11.54	38	55357	147722	70725327
Pancreatitis acute	34.35	11.54	95	55300	45129	70827920
Death	33.21	11.54	571	54824	509490	70363559
Glossodynia	33.15	11.54	13	55382	86474	70786575
Bladder cancer	33.10	11.54	53	55342	17189	70855860
Coronary artery occlusion	33.06	11.54	48	55347	14297	70858752
Treatment noncompliance	32.61	11.54	95	55300	46479	70826570
Dehydration	32.56	11.54	294	55101	225848	70647201
Product quality issue	32.50	11.54	73	55322	30488	70842561
Rhabdomyolysis	32.08	11.54	154	55241	95606	70777443
Cutaneous T-cell dyscrasia	31.94	11.54	8	55387	62	70872987
Arteriosclerosis coronary artery	31.34	11.54	50	55345	16165	70856884
Febrile neutropenia	30.34	11.54	72	55323	204246	70668803
Renal injury	30.25	11.54	49	55346	16045	70857004
Emotional distress	30.13	11.54	80	55315	37108	70835941
Spur cell anaemia	29.77	11.54	8	55387	84	70872965
Interstitial lung disease	29.62	11.54	23	55372	104662	70768387
Arthralgia	28.80	11.54	253	55142	503137	70369912
International normalised ratio increased	27.89	11.54	131	55264	80595	70792454
Arteriosclerosis	27.73	11.54	48	55347	16590	70856459
Helicobacter infection	27.67	11.54	5	55390	55651	70817398
Condition aggravated	27.63	11.54	208	55187	427427	70445622
Drug reaction with eosinophilia and systemic symptoms	27.19	11.54	6	55389	58007	70815042
Hypoacusis	26.64	11.54	63	55332	27206	70845843
Gamma-glutamyltransferase increased	26.43	11.54	4	55391	50681	70822368
Peripheral vascular disorder	26.08	11.54	31	55364	7601	70865448
Autoimmune myocarditis	25.97	11.54	10	55385	351	70872698
Injury	25.63	11.54	110	55285	65135	70807914
Alopecia	25.62	11.54	75	55320	198415	70674634
Type 2 diabetes mellitus	25.38	11.54	84	55311	43996	70829053
Stool analysis abnormal	25.36	11.54	7	55388	82	70872967
Myasthenic syndrome	25.32	11.54	12	55383	706	70872343
Neutropenia	25.30	11.54	109	55286	257047	70616002
Therapeutic product effect decreased	24.93	11.54	46	55349	142972	70730077
Oedema peripheral	24.86	11.54	280	55115	227811	70645238
Unresponsive to stimuli	24.76	11.54	93	55302	51838	70821211
Blood pressure fluctuation	24.09	11.54	8	55387	59004	70814045
Nodular rash	23.51	11.54	9	55386	311	70872738
Infection	23.50	11.54	85	55310	210700	70662349
Chronic kidney disease	23.27	11.54	102	55293	60955	70812094
Angioedema	22.94	11.54	108	55287	66502	70806547
Gastrointestinal haemorrhage	22.58	11.54	184	55211	137224	70735825
Acute coronary syndrome	22.52	11.54	49	55346	20030	70853019
Mitral valve incompetence	22.16	11.54	58	55337	26670	70846379
Discomfort	22.08	11.54	30	55365	105406	70767643
Suicide attempt	21.83	11.54	18	55377	79492	70793557
Wound	21.80	11.54	27	55368	98705	70774344
Dizziness	21.25	11.54	493	54902	463648	70409401
Anhedonia	21.11	11.54	39	55356	14174	70858875
Thrombosis	20.88	11.54	115	55280	75290	70797759
Cardiomyopathy	20.62	11.54	56	55339	26317	70846732
Intentional product use issue	20.62	11.54	39	55356	120103	70752946
Irritable bowel syndrome	20.57	11.54	7	55388	50843	70822206
Weight decreased	20.30	11.54	348	55047	310140	70562909
Occult blood positive	20.21	11.54	25	55370	6388	70866661
Drug resistance	19.94	11.54	3	55392	38187	70834862
Gastrointestinal mucosal necrosis	19.34	11.54	7	55388	206	70872843
Cellulitis	19.34	11.54	138	55257	98790	70774259
Agranulocytosis	19.23	11.54	4	55391	40294	70832755
Fear	19.17	11.54	47	55348	20764	70852285
Gout	19.15	11.54	50	55345	22956	70850093
Atrial fibrillation	19.04	11.54	224	55171	184124	70688925
Inflammation	19.01	11.54	20	55375	78645	70794404
Hyperlipidaemia	18.99	11.54	51	55344	23812	70849237
Interstitial granulomatous dermatitis	18.62	11.54	7	55388	230	70872819
Pernicious anaemia	18.43	11.54	9	55386	566	70872483
Essential hypertension	18.29	11.54	22	55373	5462	70867587
Therapeutic product effect incomplete	17.98	11.54	42	55353	119840	70753209
Leukopenia	17.93	11.54	35	55360	106525	70766524
Haemodialysis	17.93	11.54	41	55354	17325	70855724
Poor quality product administered	17.51	11.54	17	55378	3314	70869735
Cholestasis	17.06	11.54	8	55387	47864	70825185
Cytomegalovirus infection	16.93	11.54	5	55390	39753	70833296
Glycosylated haemoglobin abnormal	16.73	11.54	6	55389	172	70872877
Oedema	16.63	11.54	138	55257	103443	70769606
Toe amputation	16.51	11.54	17	55378	3556	70869493
Cognitive disorder	16.48	11.54	14	55381	60942	70812107
Epilepsy	16.29	11.54	5	55390	38779	70834270
Blood creatinine increased	16.23	11.54	177	55218	142824	70730225
Hyperinsulinaemia	16.20	11.54	6	55389	189	70872860
Hyperkalaemia	16.05	11.54	140	55255	106451	70766598
Dialysis	15.71	11.54	39	55356	17363	70855686
Blood potassium increased	15.66	11.54	52	55343	27274	70845775
Autoimmune myositis	15.65	11.54	6	55389	208	70872841
Diabetic retinopathy	15.64	11.54	15	55380	2882	70870167
Vision blurred	15.49	11.54	127	55268	94857	70778192
Hyphaema	15.40	11.54	9	55386	814	70872235
Altered state of consciousness	15.36	11.54	6	55389	40016	70833033
Ventricular hypertrophy	15.12	11.54	22	55373	6562	70866487
Aortic stenosis	15.04	11.54	22	55373	6594	70866455
Dilatation atrial	14.96	11.54	16	55379	3496	70869553
Blood loss anaemia	14.80	11.54	34	55361	14407	70858642
Hepatocellular injury	14.53	11.54	9	55386	46082	70826967
High density lipoprotein decreased	14.52	11.54	17	55378	4102	70868947
Product appearance confusion	14.48	11.54	4	55391	47	70873002
Product physical issue	14.23	11.54	16	55379	3698	70869351
Alanine aminotransferase increased	14.19	11.54	63	55332	147417	70725632
Circulatory collapse	14.15	11.54	5	55390	35469	70837580
Unevaluable event	14.14	11.54	79	55316	51984	70821065
Hypervolaemia	14.13	11.54	65	55330	39641	70833408
Carotid artery stenosis	14.04	11.54	24	55371	8212	70864837
Human anaplasmosis	13.90	11.54	4	55391	55	70872994
Nasopharyngitis	13.89	11.54	109	55286	222097	70650952
Coronary artery stenosis	13.73	11.54	29	55366	11615	70861434
Glucose urine present	13.72	11.54	11	55384	1666	70871383
Hepatic function abnormal	13.58	11.54	20	55375	67976	70805073
Multiple injuries	13.52	11.54	15	55380	3416	70869633
Osteoporosis	13.51	11.54	11	55384	48896	70824153
Gastrointestinal disorder	13.48	11.54	40	55355	105387	70767662
Full blood count decreased	13.25	11.54	45	55350	23873	70849176
Hypoglycaemic seizure	13.19	11.54	8	55387	774	70872275
Sinusitis	13.05	11.54	78	55317	169117	70703932
Fibromyalgia	12.94	11.54	11	55384	47863	70825186
Impaired healing	12.88	11.54	24	55371	74350	70798699
Urinary tract infection	12.86	11.54	269	55126	248500	70624549
Neutrophil count decreased	12.75	11.54	29	55366	83527	70789522
Cardiac arrest	12.64	11.54	185	55210	159649	70713400
Hypersensitivity	12.45	11.54	117	55278	229695	70643354
Lung disorder	12.41	11.54	22	55373	69462	70803587
Product solubility abnormal	12.33	11.54	8	55387	871	70872178
Electrocardiogram ST-T change	12.26	11.54	10	55385	1552	70871497
Anaphylactic shock	12.26	11.54	5	55390	32485	70840564
Neurotoxicity	12.25	11.54	4	55391	29822	70843227
Fluid retention	12.14	11.54	88	55307	63297	70809752
Tricuspid valve incompetence	12.14	11.54	36	55359	17781	70855268
Myopathy	12.11	11.54	37	55358	18575	70854474
Dysgeusia	12.07	11.54	73	55322	49429	70823620
Electrocardiogram QT prolonged	11.94	11.54	30	55365	83487	70789562
Knee arthroplasty	11.82	11.54	6	55389	34295	70838754
Hepatic enzyme increased	11.78	11.54	73	55322	156917	70716132
Intentional self-injury	11.73	11.54	5	55390	31645	70841404
Neuroleptic malignant syndrome	11.58	11.54	3	55392	26004	70847045

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A10BB07	ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Sulfonylureas
FDA CS	M0020795	Sulfonylurea Compounds
CHEBI has role	CHEBI:35526	antidiabetic
CHEBI has role	CHEBI:77194	ATP:pantothenate 4-phosphotransferase inhibitor
CHEBI has role	CHEBI:90415	insulin secretagogues
MeSH PA	D007004	Hypoglycemic Agents
FDA EPC	N0000175608	Sulfonylurea

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Diabetes mellitus type 2	indication	44054006	DOID:9352
Alcoholism	contraindication	7200002
Asthenia	contraindication	13791008
Myocardial infarction	contraindication	22298006	DOID:5844
Acute vomiting	contraindication	23971007
Alcohol intoxication	contraindication	25702006
Shock	contraindication	27942005
Dehydration	contraindication	34095006
Infectious disease	contraindication	40733004
Hepatic porphyria	contraindication	55056006	DOID:3133
Ketoacidosis	contraindication	56051008
Metabolic acidosis	contraindication	59455009
Hemolytic anemia	contraindication	61261009	DOID:583
Glucose-6-phosphate dehydrogenase deficiency anemia	contraindication	62403005
Hypopituitarism	contraindication	74728003	DOID:9406
Cardiogenic shock	contraindication	89138009
Kidney disease	contraindication	90708001	DOID:557
Lactic acidosis	contraindication	91273001	DOID:3650
Cobalamin deficiency	contraindication	190634004
Decompensated cardiac failure	contraindication	195111005
Disease of liver	contraindication	235856003	DOID:409
Hypoglycemic disorder	contraindication	237630007
Sepsis syndrome	contraindication	238150007
Primary adrenocortical insufficiency	contraindication	373662000
Adrenal cortical hypofunction	contraindication	386584007	DOID:10493
Fever	contraindication	386661006
Surgical procedure	contraindication	387713003
Severe diarrhea	contraindication	409587002
Traumatic injury	contraindication	417746004
Fever greater than 100.4 Fahrenheit	contraindication	426000000
Prolonged-Severe Nausea and Vomiting	contraindication
Radiography with IV Iodinated Contrast Agent	contraindication
Severe Hypoxemia	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	5.31	acidic
pKa2	11.71	acidic
pKa3	12.9	acidic
pKa4	3.19	Basic
pKa5	0.2	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Sulfonylurea receptor 1, Kir6.2	Ion channel	Q09428 Q14654	ABCC8_HUMAN KCJ11_HUMAN	BLOCKER	Kd	9.10		SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE

External reference:

ID	Source
4018508	VUID
N0000146830	NUI
D00335	KEGG_DRUG
4018508	VANDF
C0017642	UMLSCUI
CHEBI:5384	CHEBI
CHEMBL1073	ChEMBL_ID
D005913	MESH_DESCRIPTOR_UI
DB01067	DRUGBANK_ID
6821	IUPHAR_LIGAND_ID
3090	INN_ID
X7WDT95N5C	UNII
3478	PUBCHEM_CID
151822	RXNORM
4783	MMSL
574	MMSL
595	MMSL
d00246	MMSL
000913	NDDF
26124005	SNOMEDCT_US
387143009	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Glucotrol XL	HUMAN PRESCRIPTION DRUG LABEL	1	0049-0170	TABLET, EXTENDED RELEASE	2.50 mg	ORAL	NDA	27 sections
Glucotrol XL	HUMAN PRESCRIPTION DRUG LABEL	1	0049-0174	TABLET, EXTENDED RELEASE	5 mg	ORAL	NDA	27 sections
Glucotrol XL	HUMAN PRESCRIPTION DRUG LABEL	1	0049-0178	TABLET, EXTENDED RELEASE	10 mg	ORAL	NDA	27 sections
Glipizide and Metformin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	0093-7455	TABLET, FILM COATED	2.50 mg	ORAL	ANDA	27 sections
Glipizide and Metformin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	0093-7456	TABLET, FILM COATED	2.50 mg	ORAL	ANDA	27 sections
Glipizide and Metformin Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	0093-7457	TABLET, FILM COATED	5 mg	ORAL	ANDA	27 sections
Glipizide	HUMAN PRESCRIPTION DRUG LABEL	1	0378-1105	TABLET	5 mg	ORAL	ANDA	25 sections
Glipizide	HUMAN PRESCRIPTION DRUG LABEL	1	0378-1105	TABLET	5 mg	ORAL	ANDA	25 sections
Glipizide	HUMAN PRESCRIPTION DRUG LABEL	1	0378-1110	TABLET	10 mg	ORAL	ANDA	25 sections
Glipizide	HUMAN PRESCRIPTION DRUG LABEL	1	0378-1110	TABLET	10 mg	ORAL	ANDA	25 sections
Glipizide	HUMAN PRESCRIPTION DRUG LABEL	1	0591-0460	TABLET	5 mg	ORAL	ANDA	13 sections
Glipizide	HUMAN PRESCRIPTION DRUG LABEL	1	0591-0460	TABLET	5 mg	ORAL	ANDA	13 sections
Glipizide	HUMAN PRESCRIPTION DRUG LABEL	1	0591-0461	TABLET	10 mg	ORAL	ANDA	13 sections
Glipizide	HUMAN PRESCRIPTION DRUG LABEL	1	0591-0461	TABLET	10 mg	ORAL	ANDA	13 sections
GlipizideER	HUMAN PRESCRIPTION DRUG LABEL	1	0591-0844	TABLET, FILM COATED, EXTENDED RELEASE	5 mg	ORAL	ANDA	26 sections
GlipizideER	HUMAN PRESCRIPTION DRUG LABEL	1	0591-0845	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	26 sections
GlipizideER	HUMAN PRESCRIPTION DRUG LABEL	1	0591-0900	TABLET, FILM COATED, EXTENDED RELEASE	2.50 mg	ORAL	ANDA	26 sections
Glipizide	HUMAN PRESCRIPTION DRUG LABEL	1	0615-7968	TABLET	5 mg	ORAL	ANDA	20 sections
Glipizide	HUMAN PRESCRIPTION DRUG LABEL	1	0615-7969	TABLET	10 mg	ORAL	ANDA	20 sections
Glipizide	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8407	TABLET	5 mg	ORAL	ANDA	13 sections
Glipizide	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8407	TABLET	5 mg	ORAL	ANDA	13 sections
Glipizide	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8408	TABLET	10 mg	ORAL	ANDA	13 sections
Glipizide	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8408	TABLET	10 mg	ORAL	ANDA	13 sections
Glipizide	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6637	TABLET	5 mg	ORAL	ANDA	20 sections
Glipizide	HUMAN PRESCRIPTION DRUG LABEL	1	10370-745	TABLET, FILM COATED, EXTENDED RELEASE	5 mg	ORAL	ANDA	25 sections
Glipizide	HUMAN PRESCRIPTION DRUG LABEL	1	10370-745	TABLET, FILM COATED, EXTENDED RELEASE	5 mg	ORAL	ANDA	25 sections
Glipizide	HUMAN PRESCRIPTION DRUG LABEL	1	10370-746	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	25 sections
Glipizide	HUMAN PRESCRIPTION DRUG LABEL	1	10370-746	TABLET, FILM COATED, EXTENDED RELEASE	10 mg	ORAL	ANDA	25 sections
Glipizide	HUMAN PRESCRIPTION DRUG LABEL	1	10544-192	TABLET	10 mg	ORAL	ANDA	12 sections
Glipizide	HUMAN PRESCRIPTION DRUG LABEL	1	10544-193	TABLET	5 mg	ORAL	ANDA	12 sections